



Multi-Disciplinary Team Leader

Hematologic Malignancies Program search

BARBARA ANN



Karmanos

CANCER INSTITUTE

Wayne State University

WAYNE STATE

UNIVERSITY



About the Barbara Ann Karmanos Cancer Institute (KCI)

The Barbara Ann Karmanos Cancer Institute (KCI) is a unique, urban-based integrated center of research, patient care, and education located in mid-town Detroit dedicated to the prevention, early detection, treatment, and eventual eradication of cancer. KCI is affiliated with Wayne State University (WSU).

KCI has been a National Cancer Institute (NCI) - designated Comprehensive Cancer Center since 1978 and operates the only hospital in Michigan dedicated exclusively to fighting cancer. The main campus of KCI and its cancer hospital are located near major hospital networks and the WSU School of Medicine, and near major art, cultural and sports venues in the vibrant midtown area of Detroit. Since January 2014, KCI expanded its delivery of cancer care through the partnership with McLaren Health Care.

The KCI has one of the largest and best clinical trial programs in the United States. Through the commitment of 1,800 staff, including over 300 physicians and researchers and supported by thousands of volunteer and financial donors, KCI cares for approximately 12,000 new patients annually and conducts more than 400 cancer-specific clinical trials. KCI strives to prevent, detect and eradicate cancer. The long-term partnership of KCI and the WSU of Medicine enhances the collaboration between critical research and academics related to cancer care.

Seminal achievements in KCI's long history include novel anti-retroviral agents, most notably AZT; the establishment of permanent in vitro cell lines for hormone-responsive breast cancer (MCF7) and for premalignant breast lesions (MCF10); a three-dimensional in vitro tumor/stroma model for breast cancer research; combination chemoradiotherapy for head and neck, esophageal, and anal cancer; identification of breast density as a risk factor for breast cancer; positron emission tomography tracers for functional imaging; operation of one of the largest Phase I clinical trials groups with significant contributions to the success of such drugs as paclitaxel, erlotinib, lapatinib, vemurafenib, vismodegib, and trastuzumab-emtansine (TDM1); development of unique cancer vaccines and immunotherapies; molecular epidemiology studies focused on risk assessment in minority populations; and nationally recognized expertise in cancer communication and community outreach.

KCI Research Programs

<https://www.karmanos.org/?id=340&sid=1>

Key to achieving its mission is KCI's research effort, which is conducted among four interdisciplinary programs, organized to integrate basic, translational, clinical, and population research activities.

Research Programs include:

- Molecular Imaging
<http://www.karmanos.org/MI>
- Molecular Therapeutics
<http://www.karmanos.org/MT>
- Population Studies & Disparities Research
<http://www.karmanos.org/PopulationStudies>
- Tumor Biology and Microenvironment
<http://www.karmanos.org/TBM>



Partnership with McLaren Health Care (MHC)

In January 2014, Karmanos Cancer Institute executed an agreement with McLaren HealthCare (MHC) and established the largest cancer research and provider network in Michigan. This network currently covers 48 of Michigan's 83 counties with 18 cancer treatment facilities.

The partnership with a large, successful, not-for-profit, and growing health care system that shares similar values provides patient referrals, reduced cost of purchased services, and dedicated investment in cancer research. KCI is responsible for cancer research and quality of cancer care throughout MHC, thereby guaranteeing patient access to advanced treatment options. All cancer physicians across the MHC system meet the same high quality standards of performance measurement and evidence-based practice.



About Detroit

Detroit is the largest city in Michigan and a major port on the Detroit River, an international waterway that connects the western Great Lakes to Lake Erie and the Saint Lawrence Seaway. In 2010, the city had a population of 713,777—the 18th largest in the United States—and the population of the surrounding metropolitan area is more than five million. The combined Detroit–Windsor (Ontario) metropolitan area, an important commercial center on the Canada–U.S. border, has a total population of 5.7 million. Known as the nation’s traditional automotive center, Detroit is synonymous with the American automobile industry and an important source of popular music legacies celebrated in the city’s two familiar nicknames, “The Motor City” and “Motown”.

Detroit’s Midtown neighborhood is home to KCI, as well as excellent museums, theatres, libraries, concert halls, and professional sports venues. Among the cultural institutions within walking distance of KCI are the main branch of the Detroit Public Library, the Detroit Institute of Arts, the Charles H. Wright Museum of African American History, the Michigan Science Center, the Detroit Children’s Museum, and the Detroit Historical Museum.



About Wayne State University

Wayne State University, founded in 1868, is a nationally recognized public, urban research university in Detroit. Wayne State is Michigan’s only urban research university and is known internationally for its contributions to humanity, science and technology. Just as the city of Detroit is undergoing a renaissance; the university itself is in a time of significant transformation, strengthening its ability to serve students from Detroit, Michigan, and around the world. Wayne State holds the highest Carnegie Foundation for the Advancement of Teaching designations in both research and community engagement.

The 180-acre campus is the academic meeting ground for approximately 27,000 students enrolled in its 14 schools and colleges, making Wayne State University the 18th largest university in the nation. The University has more than 500,000 ft² of laboratory space committed to teaching and research. There are approximately 1,700 faculty, with 750 based in the School of Medicine, which is the largest single-campus medical school in the nation. As a result of the many interactions across the University, KCI is able to benefit from the academic cross fertilization that characterizes matrix cancer centers, while at the same time enjoying the financial and administrative flexibility of a free-standing cancer center.



The Opportunity: Multi-Disciplinary Team Leader – Hematologic Malignancies (MDT)



KCI seeks to attract a dynamic leader to build upon the historical successes of the MDT program to partner with leadership of the cancer institute and drive continued outstanding research exploration, discovery, trials and delivery of care. KCI offers an outstanding research environment, and will commit to significant startup funding and recurring support, along with a competitive salary and fringe benefit package to attract the strongest candidate.

KCI/WSU seeks a physician or physician-scientist at the senior level to head the Multidisciplinary Team (MDT) for Hematologic Malignancies at the Barbara Ann Karmanos Cancer Center. The applicant will be expected to take an active role in clinical translational research in hematologic malignancies and faculty development. The MDT consists of 7-full time faculty who concentrate on hematologic malignancies. The MDT currently operates from the new outpatient Dresner Clinic which houses both the hematologic malignancy and BMT programs. The outpatient clinic is connected to the free standing Karmanos Cancer Hospital where all the inpatient activity occurs. The center is part of a growing 12 hospital system with facilities throughout the state and is a tertiary referral center. The position comes with the substantial philanthropic support from the Dresner Foundation to be used for research, recruitment of new faculty, and patient support services. Applicants should have a proven record of success in developing clinical translational research and mentorship in the areas of hematologic malignancies.

The Joseph Dresner Family Clinic for Hematologic Malignancies & Stem Cell Transplantation

The Joseph Dresner Family Clinic for Hematologic Malignancies & Stem Cell Transplantation enables efficient and coordinated care for patients seen by both the Malignant Hematology and Stem Cell and Bone Marrow Transplant multidisciplinary teams.

Patients with multiple myeloma, amyloidosis, leukemia, lymphoma and similar cancers have efficient, one-stop access to Karmanos experts who specialize in treating those diseases. All doctors involved are able to see patients simultaneously, as well as create and implement joint treatment plans.

The Clinic will also allow Karmanos to expand its future cancer research and clinical trials focusing on leukemia, multiple myeloma, lymphoma and myelodysplastic syndrome (MDS). The center is located at Karmanos' midtown campus in Detroit. The Dresner Clinic is made possible by a generous \$5 million gift by the late Joseph Dresner, who was diagnosed with MDS in 2002.

KCI offers 13 multidisciplinary teams; each designed and staffed specifically to ensure that patients and their families get their cancer diagnosis and treatment right the first time. Each team consists of cancer specialists who are focused on your particular cancer and who have devoted their careers to fighting the very cancer with which you are confronted.

The KCI team members include specialists from each discipline including, diagnostic, medical and surgical oncology, radiation oncology; pathology; radiology; oncology nursing; supportive care; and, when appropriate, genetics.

Karmanos' Bone Marrow & Stem Cell Transplant Specialists

<http://www.karmanos.org/BMT>

KCI's Bone Marrow & Stem Cell Transplant Multidisciplinary Team includes specialists in medical hematology and oncology, infectious disease, immunotherapy, pediatrics and internal medicine who bring years of experience to the field of transplantation. The team is actively involved in clinical research in bone marrow and peripheral blood stem cells transplants.

Karmanos' Malignant Hematology Specialists

<http://www.karmanos.org/cancer-care/teams/malignant-hematology>

The KCI Malignant Hematology Multidisciplinary Team includes hematologists, medical oncologists, radiation oncologists, pathologists, cytogeneticists, pharmacists, specialized nurse practitioners, dietitians, and social workers. The team is entirely focused on treating hematologic malignancies and shares its collective expertise to create a customized treatment plan for each patient.

Cancer and conditions treated include::

- Leukemia
- Non-Hodgkin's Lymphoma
- Hodgkin's Lymphoma
- Multiple Myeloma
- Myelodysplasia (MDS)
- Amyloidosis
- Aplastic Anemia



Preferred qualifications

- PhD, MD, or MD/PhD degree or equivalent; academic accomplishments commensurate with appointment at the rank of Associate or Full Professor;
- Strong evidence of clinical productivity relevant to the major themes of the MDT Program.
- Demonstrated track record of proven leadership in relation to program development;
- Ability to create and promote program projects, and other collaboration among program members and research KCI programs;
- A strategic national academic and research/clinical leader, grounded in personal integrity with the ability to energize, inspire, and encourage faculty innovation as well as interdisciplinary collaboration;
- Demonstrated ability to manage a complex academic organization and work effectively with colleagues across divisions;
- Demonstrated success as an administrator and fiscal manager;
- Demonstrated ability to motivate key constituencies, lead the development of mutually beneficial relationships with partners, and recruit, retain, mentor, and develop superb academic faculty and co-leaders;
- Ability to foster and promote gender equity and ethnic diversity among faculty and staff to enrich the university, further its research mission, and preserve the uniqueness of KCI.





Procedure for Candidacy

Applications and nominations will be accepted until the position is filled. Confidential review of materials and screening of candidates will begin immediately.

Harris Search Associates is assisting KCI for this search. Please send application to address below or contact Jeffrey Harris, Managing Partner, for further details.

Contact Info: Jeffrey Harris, Managing Partner

Tel: 614-798-8500 ext. 125

Cell: 614-354-2100

Email: jeff@harrisandassociates.com

www.harrisandassociates.com

Harris Search Associates
I N N O V A T I O N + T A L E N T



Harris Search Associates, an IIC Partners member firm, is a leading global executive search and board advisory consulting firm. Our practice is focused on identifying and attracting leaders to support the growth of clients in the areas of research, science, engineering, academic medicine and commercial enterprises. Clients include the foremost universities, research parks, institutes, academic medical centers and commercial organizations driving global innovation and discovery.

Argentina
Australia
Austria
Belguim
Brazil
Canada
Chile
China
Colombia
Czech Republic
Denmark
Finland

France
Germany
India
Ireland
Italy
Luxembourg
Mexico
Norway
Poland
Romania
Russia
South Africa

Spain
Sweden
Switzerland
Taiwan
Thailand
The Netherlands
United Arab Emirates
United Kingdom
United States
Venezuela

KCI/WSU is an equal opportunity employer. No person will be discriminated against or harassed in employment because of race, color, religion, gender, national origin, age, disability, familial status, marital status, arrest record, height, weight, sexual orientation, qualified Vietnam era veterans, qualified special disabled veterans, recently separated veterans and other protected veterans, or any other characteristic protected by applicable federal or state law.

